Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuroscientific BiopharmaceuticalsASX:NSB EBITDA Margin % is -338.36% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Neuroscientific Biopharmaceuticals ranks worse than 76.94% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Neuroscientific Biopharmaceuticals EBITDA Margin % Related Terms
Neuroscientific Biopharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NSB vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Neuroscientific Biopharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuroscientific Biopharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuroscientific Biopharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Neuroscientific Biopharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuroscientific Biopharmaceuticals (ASX:NSB) has a EBITDA Margin % of -338.36% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neuroscientific Biopharmaceuticals and its competitors. According to the industry distribution chart, Neuroscientific Biopharmaceuticals ranks #724 out of 941 companies in the Biotechnology industry, placing it in the top 76.9%.
Is Neuroscientific Biopharmaceuticals' EBITDA Margin % too high?
Neuroscientific Biopharmaceuticals' current EBITDA Margin % is -338.36%. Based on the distribution chart, Neuroscientific Biopharmaceuticals ranks #724 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neuroscientific Biopharmaceuticals' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuroscientific Biopharmaceuticals ranks #724 out of 941 companies for EBITDA Margin %. This places Neuroscientific Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neuroscientific Biopharmaceuticals and its competitors. Neuroscientific Biopharmaceuticals's current EBITDA Margin % is -338.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuroscientific Biopharmaceuticals stock overvalued right now?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a current EBITDA Margin % of -338.36%. The current EBITDA Margin % is -338.36%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neuroscientific Biopharmaceuticals (ASX:NSB), the current EBITDA Margin % is -338.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and treatments for neurodegenerative diseases through preclinical studies of patented technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NSB has been successfully added to your 
